{"frames":[{"target":{"name":"Medical_specialties","spans":[{"start":3,"end":4,"text":"medicine"}]},"annotationSets":[{"rank":0,"score":4.786008765826715,"frameElements":[{"name":"Type","spans":[{"start":2,"end":3,"text":"molecular"}]},{"name":"Specialty","spans":[{"start":3,"end":4,"text":"medicine"}]}]}]}],"tokens":["Trends","in","molecular","medicine","."]}
{"frames":[{"target":{"name":"People","spans":[{"start":0,"end":1,"text":"Human"}]},"annotationSets":[{"rank":0,"score":33.781998711957165,"frameElements":[{"name":"Person","spans":[{"start":0,"end":1,"text":"Human"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":1,"end":2,"text":"cancer"}]},"annotationSets":[{"rank":0,"score":37.097026595515736,"frameElements":[]}]},{"target":{"name":"Roadways","spans":[{"start":10,"end":11,"text":"pathway"}]},"annotationSets":[{"rank":0,"score":68.97388972955953,"frameElements":[{"name":"Roadway","spans":[{"start":10,"end":11,"text":"pathway"}]}]}]}],"tokens":["Human","cancer","immunotherapy","with","antibodies","to","the","PD-1","and","PD-L1","pathway","."]}
{"frames":[{"target":{"name":"Death","spans":[{"start":2,"end":3,"text":"death"}]},"annotationSets":[{"rank":0,"score":45.82411829320641,"frameElements":[]}]},{"target":{"name":"Project","spans":[{"start":11,"end":12,"text":"programmed"}]},"annotationSets":[{"rank":0,"score":42.999461335921495,"frameElements":[{"name":"Activity","spans":[{"start":12,"end":28,"text":"death ligand 1 -LRB- PD-L1 -RRB- and PD-L2 , members of the CD28 and B7 families"}]},{"name":"Agent","spans":[{"start":9,"end":11,"text":"its ligands"}]}]}]},{"target":{"name":"Death","spans":[{"start":12,"end":13,"text":"death"}]},"annotationSets":[{"rank":0,"score":48.46822683190909,"frameElements":[]}]},{"target":{"name":"Membership","spans":[{"start":21,"end":22,"text":"members"}]},"annotationSets":[{"rank":0,"score":11.939513733688923,"frameElements":[{"name":"Member","spans":[{"start":21,"end":22,"text":"members"}]},{"name":"Group","spans":[{"start":22,"end":28,"text":"of the CD28 and B7 families"}]}]}]},{"target":{"name":"Kinship","spans":[{"start":27,"end":28,"text":"families"}]},"annotationSets":[{"rank":0,"score":23.424057458380233,"frameElements":[{"name":"Relatives","spans":[{"start":27,"end":28,"text":"families"}]}]}]},{"target":{"name":"Performers_and_roles","spans":[{"start":29,"end":30,"text":"play"}]},"annotationSets":[{"rank":0,"score":35.211429234033744,"frameElements":[]}]},{"target":{"name":"Judgment_communication","spans":[{"start":30,"end":31,"text":"critical"}]},"annotationSets":[{"rank":0,"score":79.81317545339422,"frameElements":[{"name":"Evaluee","spans":[{"start":31,"end":32,"text":"roles"}]}]}]},{"target":{"name":"Performers_and_roles","spans":[{"start":31,"end":32,"text":"roles"}]},"annotationSets":[{"rank":0,"score":47.4624314391166,"frameElements":[]}]},{"target":{"name":"Building_subparts","spans":[{"start":34,"end":35,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.922546899546939,"frameElements":[{"name":"Building_part","spans":[{"start":34,"end":35,"text":"cell"}]}]}]},{"target":{"name":"Biological_urge","spans":[{"start":37,"end":38,"text":"exhaustion"}]},"annotationSets":[{"rank":0,"score":39.05053656878541,"frameElements":[]}]}],"tokens":["The","programmed","death","1","-LRB-","PD-1","-RRB-","receptor","and","its","ligands","programmed","death","ligand","1","-LRB-","PD-L1","-RRB-","and","PD-L2",",","members","of","the","CD28","and","B7","families",",","play","critical","roles","in","T","cell","coinhibition","and","exhaustion","."]}
{"frames":[{"target":{"name":"Medical_conditions","spans":[{"start":6,"end":7,"text":"tumor"}]},"annotationSets":[{"rank":0,"score":31.409946575682167,"frameElements":[]}]},{"target":{"name":"Building_subparts","spans":[{"start":7,"end":8,"text":"cells"}]},"annotationSets":[{"rank":0,"score":19.185241788346342,"frameElements":[{"name":"Building_part","spans":[{"start":7,"end":8,"text":"cells"}]}]}]},{"target":{"name":"Wealthiness","spans":[{"start":16,"end":17,"text":"poor"}]},"annotationSets":[{"rank":0,"score":9.301837706530478,"frameElements":[]}]},{"target":{"name":"Medical_conditions","spans":[{"start":17,"end":18,"text":"disease"}]},"annotationSets":[{"rank":0,"score":33.88193142037607,"frameElements":[]}]},{"target":{"name":"Relational_quantity","spans":[{"start":20,"end":21,"text":"some"}]},"annotationSets":[{"rank":0,"score":15.559106734642722,"frameElements":[{"name":"Denoted_quantity","spans":[{"start":20,"end":21,"text":"some"}]}]}]},{"target":{"name":"People","spans":[{"start":21,"end":22,"text":"human"}]},"annotationSets":[{"rank":0,"score":35.33777545075857,"frameElements":[{"name":"Person","spans":[{"start":21,"end":22,"text":"human"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":22,"end":23,"text":"cancers"}]},"annotationSets":[{"rank":0,"score":39.972945145908085,"frameElements":[]}]}],"tokens":["Overexpression","of","PD-L1","and","PD-1","on","tumor","cells","and","tumor-infiltrating","lymphocytes",",","respectively",",","correlates","with","poor","disease","outcome","in","some","human","cancers","."]}
{"frames":[{"target":{"name":"Roadways","spans":[{"start":8,"end":9,"text":"pathway"}]},"annotationSets":[{"rank":0,"score":68.23039296875329,"frameElements":[{"name":"Roadway","spans":[{"start":8,"end":9,"text":"pathway"}]}]}]},{"target":{"name":"Cause_to_make_progress","spans":[{"start":11,"end":12,"text":"developed"}]},"annotationSets":[{"rank":0,"score":76.58392179419097,"frameElements":[{"name":"Project","spans":[{"start":3,"end":9,"text":"mAbs -RRB- blockading the PD-1/PD-L1 pathway"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":13,"end":14,"text":"cancer"}]},"annotationSets":[{"rank":0,"score":37.097026595515736,"frameElements":[]}]},{"target":{"name":"Cause_to_make_progress","spans":[{"start":16,"end":17,"text":"enhancing"}]},"annotationSets":[{"rank":0,"score":73.19356685079703,"frameElements":[{"name":"Project","spans":[{"start":17,"end":20,"text":"T cell functions"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":18,"end":19,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.660195229452045,"frameElements":[{"name":"Building_part","spans":[{"start":18,"end":19,"text":"cell"}]}]}]},{"target":{"name":"Contingency","spans":[{"start":19,"end":20,"text":"functions"}]},"annotationSets":[{"rank":0,"score":17.452547642634652,"frameElements":[{"name":"Determinant","spans":[{"start":18,"end":19,"text":"cell"}]}]}]}],"tokens":["Monoclonal","antibodies","-LRB-","mAbs","-RRB-","blockading","the","PD-1/PD-L1","pathway","have","been","developed","for","cancer","immunotherapy","via","enhancing","T","cell","functions","."]}
{"frames":[{"target":{"name":"Trial","spans":[{"start":1,"end":2,"text":"trials"}]},"annotationSets":[{"rank":0,"score":47.20632218920123,"frameElements":[]}]},{"target":{"name":"Evidence","spans":[{"start":9,"end":10,"text":"shown"}]},"annotationSets":[{"rank":0,"score":33.23078520784609,"frameElements":[{"name":"Proposition","spans":[{"start":10,"end":13,"text":"impressive response rates"}]},{"name":"Support","spans":[{"start":0,"end":8,"text":"Clinical trials with mAbs to PD-1 and PD-L1"}]}]}]},{"target":{"name":"Stimulus_focus","spans":[{"start":10,"end":11,"text":"impressive"}]},"annotationSets":[{"rank":0,"score":33.27610391044478,"frameElements":[{"name":"Stimulus","spans":[{"start":12,"end":13,"text":"rates"}]}]}]},{"target":{"name":"Response","spans":[{"start":11,"end":12,"text":"response"}]},"annotationSets":[{"rank":0,"score":40.75731363062538,"frameElements":[]}]},{"target":{"name":"Frequency","spans":[{"start":12,"end":13,"text":"rates"}]},"annotationSets":[{"rank":0,"score":31.937112001146772,"frameElements":[]}]},{"target":{"name":"Medical_conditions","spans":[{"start":22,"end":23,"text":"cancer"}]},"annotationSets":[{"rank":0,"score":36.3222749289382,"frameElements":[]}]},{"target":{"name":"Building_subparts","spans":[{"start":28,"end":29,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.621208365973182,"frameElements":[{"name":"Building_part","spans":[{"start":28,"end":29,"text":"cell"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":36,"end":37,"text":"cancer"}]},"annotationSets":[{"rank":0,"score":35.05253134472619,"frameElements":[]}]}],"tokens":["Clinical","trials","with","mAbs","to","PD-1","and","PD-L1","have","shown","impressive","response","rates","in","patients",",","particularly","for","melanoma",",","non-small-cell","lung","cancer","-LRB-","NSCLC","-RRB-",",","renal","cell","carcinoma","-LRB-","RCC","-RRB-",",","and","bladder","cancer","."]}
{"frames":[{"target":{"name":"Increment","spans":[{"start":0,"end":1,"text":"Further"}]},"annotationSets":[{"rank":0,"score":17.161715590052346,"frameElements":[{"name":"Class","spans":[{"start":1,"end":2,"text":"studies"}]}]}]},{"target":{"name":"Scrutiny","spans":[{"start":1,"end":2,"text":"studies"}]},"annotationSets":[{"rank":0,"score":52.65263037048189,"frameElements":[]}]},{"target":{"name":"Required_event","spans":[{"start":3,"end":4,"text":"needed"}]},"annotationSets":[{"rank":0,"score":30.39954238494978,"frameElements":[{"name":"Required_situation","spans":[{"start":0,"end":2,"text":"Further studies"}]},{"name":"Purpose","spans":[{"start":4,"end":33,"text":"to dissect the mechanisms of variable response rate , to identify biomarkers for clinical response , to develop small-molecule inhibitors , and to combine these treatments with other therapies"}]}]}]},{"target":{"name":"Scrutiny","spans":[{"start":5,"end":6,"text":"dissect"}]},"annotationSets":[{"rank":0,"score":39.55815090793064,"frameElements":[{"name":"Ground","spans":[{"start":8,"end":12,"text":"of variable response rate"}]}]}]},{"target":{"name":"Means","spans":[{"start":7,"end":8,"text":"mechanisms"}]},"annotationSets":[{"rank":0,"score":15.021403515515388,"frameElements":[{"name":"Means","spans":[{"start":7,"end":8,"text":"mechanisms"}]},{"name":"Purpose","spans":[{"start":13,"end":24,"text":"to identify biomarkers for clinical response , to develop small-molecule inhibitors"}]}]}]},{"target":{"name":"Contingency","spans":[{"start":9,"end":10,"text":"variable"}]},"annotationSets":[{"rank":0,"score":13.283703943858736,"frameElements":[]}]},{"target":{"name":"Response","spans":[{"start":10,"end":11,"text":"response"}]},"annotationSets":[{"rank":0,"score":40.75731363062538,"frameElements":[]}]},{"target":{"name":"Frequency","spans":[{"start":11,"end":12,"text":"rate"}]},"annotationSets":[{"rank":0,"score":27.635933547661377,"frameElements":[]}]},{"target":{"name":"Categorization","spans":[{"start":14,"end":15,"text":"identify"}]},"annotationSets":[{"rank":0,"score":39.202364729827806,"frameElements":[{"name":"Item","spans":[{"start":15,"end":16,"text":"biomarkers"}]}]}]},{"target":{"name":"Response","spans":[{"start":18,"end":19,"text":"response"}]},"annotationSets":[{"rank":0,"score":39.89938078188808,"frameElements":[]}]},{"target":{"name":"Cause_to_make_progress","spans":[{"start":21,"end":22,"text":"develop"}]},"annotationSets":[{"rank":0,"score":82.79788893695725,"frameElements":[{"name":"Project","spans":[{"start":22,"end":24,"text":"small-molecule inhibitors"}]}]}]},{"target":{"name":"Cause_to_amalgamate","spans":[{"start":27,"end":28,"text":"combine"}]},"annotationSets":[{"rank":0,"score":50.69236816559509,"frameElements":[]}]},{"target":{"name":"Cure","spans":[{"start":29,"end":30,"text":"treatments"}]},"annotationSets":[{"rank":0,"score":49.77677075183455,"frameElements":[]}]},{"target":{"name":"Increment","spans":[{"start":31,"end":32,"text":"other"}]},"annotationSets":[{"rank":0,"score":19.913433636580987,"frameElements":[{"name":"Class","spans":[{"start":32,"end":33,"text":"therapies"}]}]}]},{"target":{"name":"Cure","spans":[{"start":32,"end":33,"text":"therapies"}]},"annotationSets":[{"rank":0,"score":44.41832254483199,"frameElements":[]}]}],"tokens":["Further","studies","are","needed","to","dissect","the","mechanisms","of","variable","response","rate",",","to","identify","biomarkers","for","clinical","response",",","to","develop","small-molecule","inhibitors",",","and","to","combine","these","treatments","with","other","therapies","."]}
